Ghanaian research institutions and pharmaceutical companies have secured €2 million in grants to develop vaccines, medicines, and other health products for local and regional markets. This significant funding aims to strengthen the nation's pharmaceutical sector and reduce dependence on foreign imports.
Eight projects received selection under the PharmaVax Ghana programme. This initiative seeks to enhance collaboration between researchers and pharmaceutical manufacturers. Its core objective is to move promising health innovations from laboratories into commercial production. The grants were formally announced at a “Research Meets Manufacturing” ceremony held in Accra on August 19.
This investment aligns with Ghana's broader economic strategy to bolster domestic manufacturing capabilities. It specifically targets the pharmaceutical sector, a critical area for public health and economic resilience. The programme supports the National Vaccine Institute, established in 2023, in its mandate to coordinate vaccine and sera research, development, and manufacturing. This move positions Ghana as a potential hub for health product innovation in West Africa.
Health Minister Kwabena Mintah Akandoh stated the programme provides a crucial opportunity. It brings together researchers, manufacturers, government, and international partners. The goal is to translate scientific discoveries into tangible medicines and vaccines. Dr. Sodzi Sodzi-Tettey, Chief Executive of the National Vaccine Institute, affirmed Ghana possesses the necessary scientific expertise. He also highlighted an increasingly capable pharmaceutical industry ready to develop health products tailored to local needs.
The funding comes from a joint effort by the German Federal Ministry for Economic Cooperation and Development and the European Union. Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) implements the programme. Ghanaian partners are contributing an additional €425,000 to these projects. This combined investment totals €2.425 million, demonstrating a strong commitment to local innovation.
The selected projects cover a wide range of health challenges. These include malaria, chronic diseases, and infectious diseases. One project focuses on developing a fast-dissolving malaria tablet for children. This aims to simplify treatment administration and improve dosing accuracy. Another initiative will use artificial intelligence to support monoclonal antibody and diagnostic development for malaria and Mpox. Other research teams will investigate locally developed herbal treatments for conditions like hypertension and prostate health. The projects also aim to improve the stability and regulatory approval of locally produced vaccines and snake venom antiserum.
Organisers designed the programme to address a longstanding challenge. This challenge involves transforming scientific research into commercially viable products. An independent committee of nine Ghanaian experts selected the projects from 43 proposals. Selection criteria included technical merit, potential public benefit, and local manufacturer participation. The sustainability of the research beyond the grant period was also a key factor. Beyond financial support, successful teams will receive technical assistance and networking opportunities. They will also benefit from knowledge exchange, further strengthening their capabilities.
German Ambassador to Ghana, Frederik Landshöft, emphasized the partnership's role. It will connect Ghanaian research, manufacturing, and innovation with German technology and investment. The objective is to support local production of medicines and vaccines for Ghana. This also extends to potentially serving the wider West African market. This strategic collaboration is expected to foster a stronger domestic pharmaceutical industry. It will also create opportunities for Ghanaian innovations to move from research institutions into commercial production and regional markets. This initiative marks a significant step towards health security and economic growth for Ghana.